Page 4 - MemoriaDEM-Eng

ORGANIZATION

Introduction

The Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabó-

licas Asociadas (CIBERDEM) is a public research consortium which was founded on
December 3, 2007 under the funding of the Instituto de Salud Carlos III (ISCIII) and

the Ministry of Economy and Competitiveness.

CIBERDEM is made up of 31 research groups of reference based in different hospi-

tals, universities and research centres throughout Spain (the merger of two groups
in 2013 reduced the number of groups to 30). The consortium is also formed by 19

other consortium institutions from 6 Autonomous Communities.

CIBERDEM’s primary objective is to promote research on diabetes and associated
metabolic disorders by identifying the genes making one more inclined to suffer said

diseases and disorders and the environmental factors contributing to their develo-

pment, to clarify the molecular mechanisms involved in the impairment of insulin
secretion and signaling; to determine the molecular and cellular mechanisms of pan-

creatic beta cell formation and destruction; to study strategies for replacing said cell

mass; and to conduct research on the signals linking obesity and diabetes. Research
on the complications of diabetes and associated metabolic disorders is also of special

interest.

To meet its objectives, CIBERDEM seeks to generate an attractive framework for
the incorporation of basic and clinical research staff, as well as the development of

biomedical platforms suitable for conducting research of excellence in diabetes and

associated metabolic disorders. In turn, CIBERDEM promotes translational research,
favoring the transfer of acquired diabetes knowledge to other disciplines, and vice

versa.

CIBERDEM’s mission is to lead the research effort of excellence in diabetes and as-

sociated metabolic disorders, and to speed up the translation of scientific results to
clinical practice.
13
CIBERDEM conducted research activities relating to the following fields:
20
T
R
PO
• Type 1 Diabetes Mellitus. Autoimmunity. E
L R
• Type 2 Diabetes Mellitus. Insulin signaling and resistance. A
NU
• Genetics of Diabetes Mellitus. N
A
• Diabetes Mellitus. Microvascular complications. /
EM
D
• Dyslipidemia, inflammation and endothelial dysfunction. ER
B
• Pancreatic islet dysfunction, destruction and regeneration. CI

4
• Diabetes and Obesity. Biological interferences between tissues.